Company intelligence / Profile preview

Odyssey Health

Las Vegas, Nevada, USAodysseybehavioralhealth.com ↗

Ownership: Private
Development stage: Commercial

Overview

Odyssey Health developed a proprietary intranasal powder delivery platform and advanced two main programs—ONP‑002 (a neurosteroid therapy for concussion) and ONP‑001 (for Niemann-Pick type C Disease). Their lead asset, ONP‑002, demonstrated safety and tolerability in a completed Phase 1 trial with evidence of rapid brain distribution in preclinical models. In January 2024, Oragenics acquired these neurological assets to further clinical development into Phase 2 trials.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small moleculeNeurosteroidDevice
Industry: Biotech

Beyond the preview

Go deeper on Odyssey Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Odyssey Health.

Explore the full profile